Emerging targets for the treatment of depressive disorder

Expert Opinion on Therapeutic Targets

Volumn 5, Issue 5, 2001, Pages 601-612

  Macritchie, Karine A N ^a   Young, Allan H ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Cannabinoids; Corticotrophin releasing hormone antagonists; Depressive disorder; Glucocorticoid receptor; Hypothalamic pituitary adrenal axis; Monoamine hypothesis of depression; N methyl D aspartate receptor antagonists; Neuropeptide Y; Neurotrophins

Indexed keywords

EID: 0012990025     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.5.5.601     Document Type: Review

References (132)

1. MURRAY CJ, LOPEZ AD: Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet (1997) 349:1498-1504.
2. JUDD LL, AKISKAL HS, MASER JD et al.: A prospective 12 year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch. Gen. Psychiatry (1998) 55:694-700.
3. ANGST J: Major depression in 1998: are we providing optimal therapy? J. Clin. Psychiatry (1999) 60(Suppl. 6):5-9.
4. NIERENBERG AA, WHITE K: What next? A review of pharmacological strategies for treatment-resistant depression. Psychopharmacol. Bull. (1990) 26(4):429-460.
5. CORNWALL PL, SCOTT J: Partial remission in depressive disorders. Acta Psychiatr. Scand. (1997) 95:265-271.
6. COWEN PJ: Back to the future: the neurobiology of major depression Psychol. Med. (1998) 28(2):253-255.
7. NUTT DJ, FORSHALL S, BELL C et al.: Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur. Neuropsychopharmacol. (1999) 9(Suppl. 3):81-86.
8. HIRSCHFELD RMA: History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry (2000) 61(Suppl. 6):4-6.
9. DELGADO PL: Depression. The case for a monoamine deficiency. J. Clin. Psychiatry (2000) 61(Suppl. 6):7-11.
10. MENKES DB, MACDONALD JA: Interferons, serotonin and neurotoxicity. Psychol Med. (2000) 30:259-268.
11. ERIKSSON E, SUNDBLAD C, YONKERS KA, STEINER M: Premenstrual dysphoria and related conditions: symptoms, pathophysiology and treatment. In: Mood disorders in Women. Martin Dunitz Ltd, London, (2000):279-280.
12. BERGER M, GASTPAR M: Trimipramine: a challenge to current concepts on antidepressives. Eur. Arch. Psychiatry Clin. Neurosci. (1996) 246:235-239.
13. DAVIES DL, SHEPHERD M: Reserpine in the treatment of anxious and depressed patients. Lancet (1955) ii:117-121.
14. ANDERSON IM, NUTT DJ, DEAKIN JFW: Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J. Psychopharmacol. (2000) 14(1):3-20.
15. JONES MT, GILLHAM B, CAMPBELL EA, AL-TAHER AR, CHUANG TT, DI SCIULLO A: Pharmacology of neural pathways affecting CRH secretion. Ann. NY Acad. Sci. (1987) 512:162-175.
16. SAPOLSKY RM, KREY LC, MCEWEN BS: The neuroendocrinology of stress and ageing: the glucocorticoid cascade hypothesis. Endocr. Rev. (1986) 7(3):284-301.
17. JACOBSON L, SAPOLSKY R: The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr. Rev. (1991) 12(2):118-134.
18. GIBBONS JL: Cortisol secretion rate in depressive illness. Arch. Gen. Psychiatry (1964) 10:572-575.
19. OWENS MJ, NEMEROFF CB: The role of CRF in the pathophysiology of affective disorders: In: Laboratory and Clinical Studies (Volume 172). John Wiley and Sons. New York (1993).
20. DEUSCHLE M, SCHWEIGER U, WEBER B et al.: Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J. Clin. Endocrinol. Metab. (1997) 82(1):234-238.
21. NEMEROFF CB, WIDERLOV E, BISETTE G et al.: Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 226(4680): 1342-1344.
22. ZHOU DF, SHEN YC, SHU LN, LO HC: Dexamethasone suppression test and urinary MHPGX SO4 determination in depressive disorders. Biol. Psychiatry (1987) 22(7):883-891.
23. ZOBEL AW, YASSOURIDIS A, FRIEBOES RM, HOLSBOER F: Prediction of medium term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am. J. Psychiatry (1999) 156(6):949-951.
24. HOLSBOER F, LIEBL, R, HOFSCHUSTER E: Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement. J. Affect. Disord. (1982) 4:93-101.
25. HEUSER IJ, SCHWEIGER U, GOTTHARDT U et al.: Pituitary-adrenal system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and in normal controls. Am. J. Psychiatry. (1996) 153(1):93-99.
26. STECKLER T, HOLSBOER F, REUL JMHM: Glucocorticoids and depression. In: Balliere's Clinical Endocrinology and Metabolism. Harcourt Publishers Ltd. (1999):606.
27. REUL JMHM, STEC I, SODER M, HOLSBOER F: Chronic treatment of rats with antidepressant amitriptyline attenuates the activity of the hypothalamic pituitary adrenocortical system. Endocrinology (1993) 133:312-320.
28. REUL JMHM, LAVEUR MS, GRIGORIADIS DE, DE SOUZA EB, HOLSBOER F: Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology (1994) 60(5):509-519.
29. PEPIN MC, BEAULIEU S, BARDEN N: Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res. Mol. Brain Res. (1989) 6(1):77-83.
30. SECKL JR, FINCK G: Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology (1992) 55(6):621-626.
31. ROSSBY SP, NALEPA I, HUANG M et al.: Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. Brain Res. (1995) 687(1-2):79-82.
32. PEIFFER A, VEILLEUX S, BARDEN N: Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology (1991) 16(6):505-515.
33. PRZEGALINSKI E, BUDZISZEWSKA B, SIWANOWICZ J, JAWORSKA L: The effect of repeated combined treatment with nifedipine and antidepressant drugs or electroconvulsive shock on the hippocampal corticosteroid receptors in rats. Neuropharmacology (1993) 32(12):1397-1400.
34. REUL JMHM, GESING A, DROSTE S et al.: The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. Eur. J. Pharmacol. (2000) 405(1-3):235-249.
35. MURPHY BEP: Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology (1997) 22(Suppl. 1):S125-132.
36. BERTAGNA X, ESCOUROLLE H, PINQUIER JL et al.: Administration of RU486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. J. Clin. Endocrinol. Metab. (1994) 78(2):375-380.
37. LAUE L, LOTZE MT, CHROUSOS GP, BARNES K, LORIAUX DL, FLEISCHER TA: Effect of chronic treatment with the glucocorticoid antagonist RU486 in man: toxicity, immunological and hormonal aspects. J. Clin. Endocrinol. Metab. (1990) 71(6):1474-1480.
38. TIMPL P, SPANAGEL R, SILLABER I et al.: Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. (1998) 19(2):162-166.
39. OWENS MJ, NEMEROFF CB: Corticotropin-releasing factor antagonists-therapeutic potential in the treatment of affective disorders. CNS Drugs (1999) 12:85-92.
40. ZOBEL AW, NICKEL T, KUNZEL HE et al.: Effects of the high affinity corticotrophin releasing Hormone receptor antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. (2000) 34(3):171-181.
41. MOFFOOT AP, O'CARROLL RE, BENNIE J et al.: Diurnal variation of mood and neuropsychological function in major depression with melancholia. J. Affect. Disord. (1994) 32(4):257-269.
42. JACKSON IMD: The thyroid axis and depression. Thyroid (1998) 8(10):951-956.
43. DINAN TG: Psychoneuroendocrinology of depression - growth hormone. Psychiatr. Clin. North Am. (1998) 21(2):325.
44. JOFFE RT, SOKOLOV ST, SINGER W: Thyroid hormone treatment of depression. Thyroid (1995) 5(3):235-239.
45. MAMOUNAS LA, BLUE ME, SIUCIAK JA, ALTAR CA: Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in the rat brain. J. Neurosci. (1995) 15(12):7929-7939.
46. REID IC, STEWART CA: How antidepressants work. New perspectives on the pathophysiology of depressive disorder. Br. J. Psychiatry (2001) 178:299-303.
47. SHAH PJ, EBMEIER KP, GLABUS MF, GOODWIN GM: Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic imaging study. Br. J. Psychiatry (1998) 172:527-532.
48. PAVLIDES C, KIMURA A, MAGARINOS AM, MCEWEN BS: Opposing roles of Type I and Type II adrenal steroid receptors in hippocampal long-term potentiation. Neuroscience (1995) 68(2):387-394.
49. NIBUYA M, MORINOBU S, DUMAN RS: Regulation of BDNF and trkB mRNA chronic elecuoconvulsive seizure and antidepressant treatments. J. Neurosci. (1995) 15:7539-7547.
50. NIBUYA M, NESTLER EJ, DUMAN RS: Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. (1996) 16(7):2365-2372.
51. DUMAN RS, HENINGER GR, NESTLER EJ: A molecular and cellular theory of depression. Arch. Gen. Psychiatry (1997) 54(7):597-606.
52. MAMOUNAS LA, BLUE ME, SIUCIAK JA, ALTAR, CA: BDNF promotes survival and sprouting of serotonergic axons in the rat brain. J. Neurosci. (1995) 15(12):7929-7939.
53. SKLAIR-TAVRON L, NESTLER EJ: Opposing effects of morphine and the neurotrophins NT-3, NT-4 and BDNF on locus coeruleus neurons in vitro. Brain Res. (1995) 702:117-125.
54. ZELLER E, STEIF HJ, PFLUG B, SASTRE-Y-HERNANDEZ M: Results of a phase-II study of the antidepressant effect of Rolipram. Pharmacopsychiatry (1984) 17(6):188-190.
55. SCOTT AI, PERINI AF, SHERING, PA, WHALEY LJ: In-patient major depression: is rolipram as effective as amitriptyline? Eur. J. Clin. Pharmacol. (1991) 40(2):127-129.
56. HEBENSTREIT GF, FELLERER K, FICHTE K et al.: Rolipram in major depressive disorder-results of a double-blind comparative study with imipramine. Pharmacopsychiatry (1989) 22(4):156-60.
57. FLEISCHHACKER WW, HINTERHUBER H, BAUER H et al.: A multi-centre double-blind study of 3 different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology (1992) 26(1-2):59-64.
58. ORREGO F, VILLANUEVE S: The chemical nature of the main central excitatory neurotransmitter: a critical appraisal based upon release studies and synaptic vesicle localization. Neuroscience (1993) 56(3):539-555.
59. LEVINE ES, CROZIER RA, BLACK IB, PLUMMER MR: Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D-aspartic acid receptor activity. Proc. Natl. Acad. Sci. USA (1998) 95(17):10235-10239.
60. TRULLAS R: Functional NMDA Antideptessants. A New Class of Antidepressant Agent. In: Antidepressants. New pharmacological strategies. P Skolnick (Ed.), Humana Press, Totowa, New Jersey, USA (1997):109.
61. MONYER H, BURNASHEV N, LAURIE DJ, SAKMANN, B, SEEBURG PH: Developmental and regional expression in the rat-brain and functional properties of 4 NMDA receptors. Neuron (1994) 12(3):529-540.
62. PETRIE RXA, REID IC, STEWART CA: The N-methyl-D-aspartate receptor, synaptic plasticity and depressive disorder. A critical review. Pharmacol. Ther. (2000) 87(1):11-25.
63. COOPER JR, BLOOM FE, ROTH RH: The NMDA Rcceptor-Ionophor Complex. In: The Biochemical Basis of Neuropharmacology. (Edition 7). Oxford University Press, New York (1996).
64. PAUL IA: Animal analogs of major depression. Forced swim test. NMDA Receptors and Affective Disorders. In: Antidepressants. New Pharmacological Strategies. Humana Press, Totowa, New Jersey (1997):148.
65. PAUL IA: Animal analogs of major depression. Chronic mild stress-induced deficits in sucrose drinking. NMDA Receptors and Affective Disorders. In: Antidepressants. New Pharmacological Strategies. Humana Press, Totowa, New Jersey (1997):149.
66. HARADAHIRA T, ZHANG MR, MAEDA J et al.: A prodrug of NMDA/ glycine site antagonist, I-703,717. with improved bbb permeability: 4-acetoxy derivative and its positron-emitter labelled analog. Chem. Pharm. Bull. (Tokyo) (2001) 49(2):147-150.
67. OWENS J, TEBBUTT AA, MCGREGOR AL, KODAMA K et al.: Synthesis and binding characteristics of N-(1-napthyl)-N′-(3-[I-125]-iodophenyt)-N′-methylguanidine ([I-125]-CNS 1261): a potential SPECT agent for imaging NMDA receptor activation. Nucl. Med. Biol. (2000) 27(6):557-564.
68. NOWAK G, ORDWAY GA, PAUL LA: Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. (1995) 675(1-2):157-164.
69. 3H]MK-801 in brain samples from drug-free depressed suicides. Brain Res. (1993) 616(1-2):138-143.
70. PAUL IA: NMDA Receptors and Affective Disorders. In: Antidepressants. New pharmacological strategies. P Skolnick (Ed.), Humana Press, Totowa, New Jersey, USA (1997):147.
71. NOWAK G, TRULLAS R, LAYER RT, SKOLNICK P, PAUL IA: Adaptive changes in the N-methyl-D-aspartate (NMDA) receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J. Pharmacol. Exp. Ther. (1993) 265(3):1380-1386.
72. PAUL IA, LAYER RT, SKOLNICK P et al.: Adaptation of N-methyl-D-aspartate (NMDA) receptor complex in rat frontal cortex following treatment with electroconvulsive shock or imipramine. Eur. J. Pharmacol. (1993) 247(3):305-311.
73. PAUL IA, NOWAK G, LAYER RT, POPNIK, SKOLNICK P: Adaptation of the N-methyl-D-aspanate (NMDA) receptor complex following chronic antidepressant treatments. J. Pharmacol. Exp. Ther. (1994) 269(1):95-102.
74. MASSICOTTE G, BERNARD J, OHAYON M: Chronic effects of trimipramine, an antidepressant, on hippocampal synaptic plasticity. Behavioural Neural Biology (1993) 59(2):100-106.
75. MAJ J, ROGOZ Z, SKUZA G: The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists in the forced swimming test. Pol. J. Pharmacol. Pharmaceut. (1992) 44(4):337-346.
76. MAJ J, ROGOZ Z, SKUZA G, SOWINSKA H: Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Eur. Neuropsychopharmacol. (1992) 2:37-41.
77. BERMAN RM, CAPPIELLO A, ANAND A et al.: Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry (2000) 47(4):351-354.
78. LAHTI AC, WARFEL D, MICHAELIDIS T, WEILER MA, FREY K, TAMMINGA CA: Long-term outcome of patients who receive ketamine during research. Biol. Psychiatry (2001) 49(10):869-875.
79. GREENE P, EARL NL, ASCHER JA et al.: Mood stabilisation with lamotrigine in rapid-cycling disorder, a double-blind, placebo-controlled study. In: American Psychiatric Association Annual Meeting 13-18 May (2000) NR 288:190.
80. CALABRESE JR, BOWDEN C, SACHS GS, ASCHER JA, MONAGHAN E, RUDD GD: A double-blind, placebo controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J. Clin. Psychiatry (1999) 60(2):79-88.
81. ANAND A, CHARNEY DS, OREN DA et al.: Attenuation of the neuropsychiatric effects of ketamine with lamotrigine-support for hyperglutamergic effects of N-methyl-D-aspartate receptor antagonists. Arch. Gen. Psychiatry (2000) 57(3):270-276.
82. ROBINSON RG, STARR LB, KUBOS KL, PRICE TR: A two-year longitudinal study of post-stroke mood disorders: findings during the initial evaluation. Stroke (1983) 14(5):736-741.
83. ROBINSON RG, BOLDUC PL, PRICE TR: Two-year longitudinal study of poststroke mood disorders: diagnosis and outcome at one and two years. Stroke (1987) 18(5):837-843.
84. FOSSOM LH, VON LUBITZ DK, LIN RC, SKOLNICK P: Neuroprotective actions of 1-aminocyclopropanecarboxylic acid (ACPC): a partial agonist at strychinine-insensitive glycine sites. Neurol Res. (1995) 17(4):265-269.
85. VON LUBITZ DK, LIN RCS, MCKENZIE RJ, DEVLIN TM, MCCABE RT, SKOLNICK P: A novel treatment of global cerebral ischaemia with a glycine partial agonist. Eur. J. Pharmacol. (1992) 219(1):153-158.
86. KLODZINSKA A, CHOJNACKAWOJCIK E, PALUCHA A, BRANSKI P, POPIK P, PILC A: Potential anti-anxiety, anti-addictive effects of LY 354740, a selective II glutamate metabotropic receptor agonist in animal models. Neuropharmacology (1999) 38(12):1831-1839.
87. SHEKHAR A, KEIM SR: LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology (2000) 39(7):1139-1146.
88. HELTON DR, TIZZANO JP, MONN JA, SCHOEPP DD, KALLMAN MJ: Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. (1998) 284(2):651-660.
89. FERRIS P, SEWARD E, DAWSON GR: Interactions between LY354740, a group II metabotropic agonist and the GABAA benzodiazepine receptor complex in the rat elevated plus-maze. J. Psychopharmacology (2001) 15(2):76-82.
90. MAGGIO JE: Tachykinins. Ann. Rev. Neurosci. (1988) 11:13-28.
91. CHANG MM, LEEMAN SE: Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterisation as substance P. J. Biol. Chem. (1970) 245(18):4784-4790.
92. 1 receptor antagonists as potential antidepressants. Ann. Rev. Pharmacol. Toxicol. (2001) 41:877-906.
93. TEXIERA RM, SANTOS ARS, RIBEIRO SJ, CALIXTO JB, RAE GA, DE LIMA TC: Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behaviour in mice. Eur. J. Pharmacol (1996) 311(1):7-l4.
94. ELLIOTT PJ: Place aversion induced by the substance P analogue dimethyl-C7 is not state dependent-implication of substance P in aversion. Exp. Brain Res. (1988) 73(2):354-356.
95. HASENOHRL RU, JENTJENS O, DE SOUZA SMA, TOMAZ C, HUSTON JP: Anxiolytic-like action of neurokinin substance P administered systemically or into the nucleus basalis magnocellularis region. Eur J. Pharmacol (1998) 354(2-3):123-133.
96. KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for antidepressant activity by blockade central substance P receptors. Science (1998) 281(5383):1624-1625.
97. RUPNIAK NM, CARLSON EC, HARRISON T et al.: Pharmacological blockade or genetic deletion of substance P (NK1) receptors attenuates neonatal vocalisation in guinea pigs and mice. Neuropharmacology (2000) 39(8):1413-1421.
98. GRIEBEL G: Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol. Ther. (1999) 82(1):1-61.
99. TATEMOTO K, CARLQUlST M, MUTT V: Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature (1982) 296(5858):659-660.
100. KRYSIAK R, OBUCHOWICZ E, HERMAN ZS: Interactions between the neuropeptide system and the hypothalamic-pituitary-adrenal axis. Eur. J. Endocrinol. (1999) 140(2):130-136.
101. WIDDOWSON PS, ORDWAY GA, HALARIS AE: Reduced Neuropeptide Y concentrations in suicide brain. J. Neurochem. (1992) 59(1):73-80.
102. HEILIG M, WIDERLOV E: Neuropeptide Y: an overview of central distribution, functional aspects and possible involvement in neuropsychiatric illnesses. Acta Psychiatrica Scandinavica (1990) 82(2):95-114.
103. HUSUM H, MIKKELSEN JD, HOGG S, MATHE AA, MORK A: Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology (2000) 39(8):1463-1473.
104. GLASSMAN AH, HELZER JE, COVEY LS et al.: Smoking, smoking cessation and major depression. JAMA (1990) 264(12):1546-1549.
105. BRESLAU N, KILBEY M, ANDRESKI P: Nicotine dependence, major depression and anxiety in young adults. Arch. Gen. Psychiatry (1991) 48(12):1069-1074.
106. COVEY LS, CLASSMAN AH, STETNER F: Major depression following smoking cessation. Am. J. Psychiatry (1997) 154(2):263-265.
107. QUATTROCKI E, BAIRD A, YURGELUN-TODD D: Biological aspects of the link between smoking and depression. Harv. Rev. Psychiatry (2000) 8(3):99-110.
108. WONNACOT S: Presynaptic nicotinic ACh receptors. Trends Neurosci. (1997) 20:92-98.
109. HARRISON PJ: The neuropathology of schizophrenia-a critical review of the data and their interpretation. Brain (1999) 122(4):593-624
110. MCALLISTER-WILLIAMS RH, ANDERSON AJ, YOUNG AH: Conicosterone selectively attenuates 8-OH-DPAT-mediated hypothermia in mice. Int. J. Neuropsychopharmacology (2001) 4(1):1-8.
111. COURT J. CLEMENTI F: Distribution of nicotinic subtypes in human brain. Alzheimer Dis. Assoc. Disord. (1995) 9(Suppl. 2):6-14.
112. COURTJA, PERRY EK: In: CNS Neurotransmission and Neuromodulation. Stone TW (Ed.) CRC Press (1995):85-104.
113. RUBBOLI F, COURT JA, SALA C et al.: Distribution of nicotinic receptors in the human hippocampus and thalamus. Eur. J. Neurosci. (1994) 6(10):1596-1604.
114. CLARKE PB, REUBEN M: Release of [3-H)-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3-H]-dopamine release. Br. J. Pharmacology (1996) 117(4):595-606.
115. LENOVERE N, ZOLI M, CHANGEUX JP et al.: Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur. J. Neurosci. (1996) 8(11):2428-2439.
116. MAGGI L, PALMA E, MILEDI, R, EUSEBI F: Effects of fluoxerine on wild and mutant neuronal alpha (7) nicotinic receptors. Mol. Pychiatry (1998) 3(4):350-355.
117. SLEMMER JE, MARTIN BR, DAMAJ MI: Bupropion is a nicotinic antagonist.J. Pharmacol. Exp. Ther. (2000) 295(1):321-327.
118. FRYER JD, LUKAS RJ: Antidepressants non-competitively inhibit nicotinic acetylcholine receptor function. J. Neurochem. (1999) 72(3):117-1124.
119. FERGUSON FM, BRODKIN JD, LLOYD GK, MENZAGHI F: Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist SIB-1508Y in the learned helplessness rat model of depression. Psychopharmacology (2000) 152(3):295-303.
120. SALIN-PASCUAL R, DRUCKER CR: A novel effect of nicotine on mood and sleep in major depression. Neuroreport (1998) 9(1):57-60
121. SALIN-PASCUAL R, ROSAS M, JIMENEZ GEICHIET AL: Antidepressant effect of transdermal nicotine patches in non-smoking patients with major depression. J. Clin. Psychiatry (1996) 57:387-389.
122. SALIN-PASCUAL R, DE LA FUENTE JR, GALICIA-POLO L, DRUCKER-COLIN R: Effects of transdermal nicotine on mood and sleep in non-smoking major depressed patients. Psychopharmacology (1995) 121(4):476-479.
123. PERTWEE RG: Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors: an overview. In: Cannabinoid Receptors. Pertwee R (Ed.), Harcourt Brace (1995):1-34.
124. GRINSPOON L, BAKALAR JB: In: Marihuana, The Forbidden Medicine. Yale University Press, New Haven and London (1993).
125. REGELSON W, BUTLER JR, SCHULZ J et al.: Delta-9-THC as an effective antidepressant and appetite stimulating agent in advanced cancer patients. In: The Pharmacology of Marihuana. Braude MC, Szara S (Eds.), Raven Press, New York. (1976):763-775.
126. FABREL LF, MCLENDON D: The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J. Clin. Pharmacol. (1981) 21(8-9s):377S-382S.
127. ILARIA RL, THORNBY JI, FANN WE: Nabilone, a cannabinol derivative, in the treatment of anxiety neurosis. Curr. Ther. Res. (1981) 29:943-949.
128. GEORGE MS, SACKEIM HA, RUSH A et al.: Vagus nerve stimulation: a new tool for brain research and therapy. Biol. Psychiatry (2000) 47:287-295.
129. RUSH AJ, GEORGE MS, SACKEIM HA et al.: Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicentre study. Biol. Psychiatry (2000) 47:276-286.
130. REID PD, SHAJAHAN PM, GLABUS MF, EBMEIER KP: Transcranial magnetic stimulation in depression. Br. J. Psychiatry (1998) 173(12):449-452.
131. PASCUAL-LEONE A, RUBIO B, PALLARDO F, CATALA MD: Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet (1996) 348:233-237.
132. GEORGE MS, WASSERMANN EM, KIMBRELL TA et al.: Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression. A placebo-controlled crossover trial. Am. J. Psychiatry (1997) 154:1752-1756.